IL161229A0 - Methods and compositions relating to restricted expression lentiviral vectors and their applications. - Google Patents

Methods and compositions relating to restricted expression lentiviral vectors and their applications.

Info

Publication number
IL161229A0
IL161229A0 IL16122902A IL16122902A IL161229A0 IL 161229 A0 IL161229 A0 IL 161229A0 IL 16122902 A IL16122902 A IL 16122902A IL 16122902 A IL16122902 A IL 16122902A IL 161229 A0 IL161229 A0 IL 161229A0
Authority
IL
Israel
Prior art keywords
applications
methods
lentiviral vectors
restricted expression
compositions relating
Prior art date
Application number
IL16122902A
Other languages
English (en)
Original Assignee
Inst Clayton De La Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Clayton De La Rech filed Critical Inst Clayton De La Rech
Publication of IL161229A0 publication Critical patent/IL161229A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16122902A 2001-10-02 2002-09-30 Methods and compositions relating to restricted expression lentiviral vectors and their applications. IL161229A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32659301P 2001-10-02 2001-10-02
PCT/US2002/031023 WO2003029412A2 (en) 2001-10-02 2002-09-30 Restricted expression lentivial vectors

Publications (1)

Publication Number Publication Date
IL161229A0 true IL161229A0 (en) 2004-09-27

Family

ID=23272874

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16122902A IL161229A0 (en) 2001-10-02 2002-09-30 Methods and compositions relating to restricted expression lentiviral vectors and their applications.

Country Status (12)

Country Link
US (4) US7198950B2 (xx)
EP (1) EP1438075A4 (xx)
JP (1) JP2005504539A (xx)
KR (1) KR20040054699A (xx)
CN (1) CN1606456A (xx)
AU (1) AU2002343458B2 (xx)
CA (2) CA2915676C (xx)
IL (1) IL161229A0 (xx)
NZ (1) NZ532060A (xx)
RU (1) RU2305708C2 (xx)
WO (1) WO2003029412A2 (xx)
ZA (1) ZA200402527B (xx)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003268546A1 (en) * 2002-09-06 2004-03-29 Massachusetts Institute Of Technology Lentiviral vectors, related reagents, and methods of use thereof
ES2348868T3 (es) * 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
WO2004098531A2 (en) * 2003-05-05 2004-11-18 Virxsys Corporation Increased transduction using abc transporter substrates and/or inhibitors
US20070202505A1 (en) * 2003-09-08 2007-08-30 Alex Chenchik Methods for gene function analysis
JP2006254872A (ja) * 2005-03-18 2006-09-28 Kenzaburo Tani 幹細胞分化の促進方法
US20070054872A1 (en) * 2005-08-24 2007-03-08 Mirus Bio Corporation Regulatable or conditional expression systems
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
KR100987004B1 (ko) * 2007-02-27 2010-10-11 (주) 에빅스젠 Ａｉｄｓ 예방 및 치료 물질 스크리닝용 재조합 포유동물세포 및 이를 이용한 스크리닝 방법
WO2008105604A1 (en) * 2007-02-27 2008-09-04 Avixgen Inc. Recombinant mammalian cell for screening a substance preventing and treating aids and screening method using the same
WO2008137115A1 (en) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
WO2008134878A1 (en) * 2007-05-04 2008-11-13 University Health Network Compositions and methods for cancer treatment
EP2019134A1 (en) * 2007-07-26 2009-01-28 Vision 7 GmbH Gene therapy of chronic granulomatous disease
US8617534B2 (en) 2007-11-16 2013-12-31 San Diego State University (Sdsu) Foundation Compositions and method for manipulating PIM-1 activity in circulatory system cells
US9005599B2 (en) 2008-04-21 2015-04-14 Tissue Regeneration Therapeutics Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
WO2009137598A2 (en) * 2008-05-06 2009-11-12 University Of Chicago Methods and composition for modulating hematopoietic stem cell migration
US20100183558A1 (en) * 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
PT3031907T (pt) 2008-11-06 2021-01-28 Univ Indiana Res & Tech Corp Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas
US10287579B2 (en) 2009-04-30 2019-05-14 Ospedale San Raffaele S.R.L. Gene vector
RU2540021C2 (ru) * 2009-07-20 2015-01-27 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека
AU2010322723B9 (en) * 2009-11-19 2015-03-05 Momotaro-Gene Inc. System for increasing gene expression and vector comprising the system
KR20130010121A (ko) 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
WO2011146885A2 (en) * 2010-05-21 2011-11-24 Virxsys Corporation Compositions and methods for lentiviral expression of apoa-1 or variants thereof using spliceosome mediated rna trans-splicing
AU2011336467A1 (en) 2010-12-01 2013-07-04 Spinal Modulation, Inc. Agent delivery systems for selective neuromodulation
WO2013045639A1 (en) * 2011-09-29 2013-04-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) LENTIVIRAL VECTORS PSEUDOTYPED WITH MUTANT BaEV GLYCOPROTEINS
MX355625B (es) * 2011-12-22 2018-04-25 Hoffmann La Roche Organizacion de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
CN103638604B (zh) * 2012-12-31 2016-05-04 深圳先进技术研究院 一种助行***
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
US10071114B2 (en) 2014-09-07 2018-09-11 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
AU2016285473A1 (en) * 2015-07-01 2018-01-18 The Regents Of The University Of California Retroviral vectors containing a reverse orientation human ubiquitin C promoter
RU2646111C2 (ru) * 2015-12-29 2018-03-01 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Экспрессионный плазмидный лентивирусный вектор для гетерологической экспрессии рекомбинантного человеческого белка cd44
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
PL3445406T3 (pl) 2016-04-20 2022-02-07 Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas, O.A., M.P. Kompozycje i sposoby zwiększonej ekspresji genów PKLR
CN106086077A (zh) * 2016-07-05 2016-11-09 北京普瑞金科技有限公司 用于car‑t制备的慢病毒载体及其构建方法和应用
BR112019013862A2 (pt) 2017-01-07 2020-04-14 Selecta Biosciences Inc dosagem padrão de imunossupressores acoplados a nanocarreadores sintéticos
EP3565564A4 (en) * 2017-01-09 2020-09-23 American Gene Technologies International Inc. HIV IMMUNOTHERAPY WITHOUT PRE-IMMUNIZATION STEP
WO2018140946A1 (en) 2017-01-30 2018-08-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant virus vectors for the treatment of glycogen storage disease
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University IMMUN REGULATORY MOLECULES AND THEIR USES
WO2019075360A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
JP7403461B2 (ja) 2017-10-16 2023-12-22 セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． ピルビン酸キナーゼ欠損症を治療するためのｐｋｌｒ送達用レンチウイルスベクター
RU2697797C2 (ru) * 2017-12-28 2019-08-19 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Генетическая конструкция для индукции пролиферации периферических моноцитов in vitro
CN111757933A (zh) 2018-02-05 2020-10-09 艾比克斯生物科学有限责任公司 Pcbp1用于治疗过度增殖性疾病的用途
CN112384204B (zh) 2018-02-26 2023-03-14 安托瑞斯公司 致耐受性脂质体及其使用方法
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
SG11202102012SA (en) * 2018-08-28 2021-04-29 Pharos Vaccine Inc Improved lentiviral vector
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
CN109971787A (zh) * 2019-04-17 2019-07-05 北京美康基免生物科技有限公司 一种cybb慢病毒载体、慢病毒载体转染的干细胞及其制备方法和应用
TW202106704A (zh) 2019-04-26 2021-02-16 美商艾洛基因醫療公司 抗利妥昔單抗嵌合抗原受體及其用途
JP2022531201A (ja) 2019-04-28 2022-07-06 セレクタ バイオサイエンシーズ インコーポレーテッド ウイルス導入ベクターに対する既存の免疫を伴う対象の処置のための方法
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
TW202115126A (zh) 2019-06-11 2021-04-16 美商舒爾人類基因療法公司 用於治療血漿激肽釋放酶失調所介導之疾病的抗體腺相關病毒載體遞送
US20220372511A1 (en) * 2019-06-14 2022-11-24 The Regents Of The University Of California Dna construct for targeting therapeutic molecules to diseased tissue by immune cells
WO2021026488A2 (en) * 2019-08-07 2021-02-11 Ibex Biosciences, Llc Use of pcbp1 to generate induced pluripotent stem cells while inhibiting oncogenesis
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
AU2020361533A1 (en) 2019-10-08 2022-04-28 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
CN115176022A (zh) 2019-10-23 2022-10-11 夏尔人类遗传性治疗公司 用于遗传性血管性水肿的基于腺相关病毒载体的基因疗法
EP4058068A4 (en) * 2019-11-12 2024-03-13 The Regents Of The University Of California LENTIVIRAL VECTORS USED IN HEMATOPOIETIC STEM CELLS TO TREAT CHRONIC X-LINKED GRANULOMATOUS DISEASE
CN110881442A (zh) * 2019-12-11 2020-03-17 湖南蒙生生物科技股份有限公司 一种使用草本生物调理粉生产生态甲鱼的方法
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
JP2023538519A (ja) 2020-08-07 2023-09-08 スペースクラフト セブン リミテッド ライアビリティ カンパニー Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
US20220186252A1 (en) 2020-12-16 2022-06-16 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
CA3217862A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
JP2024527559A (ja) 2021-07-01 2024-07-25 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞及び関連する方法
CN113308494A (zh) * 2021-07-14 2021-08-27 卡瑞济(北京)生命科技有限公司 一种更安全的地中海贫血基因治疗载体、构建方法及其应用
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
AU2022325232A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
EP4384544A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
EP4384193A2 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023114918A1 (en) 2021-12-16 2023-06-22 Ludwig Institute For Cancer Research Ltd Antisense transfer vectors and methods of use thereof
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US5019384A (en) * 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
US5885570A (en) * 1991-01-23 1999-03-23 The General Hospital Corporation Induction of tolerance with modified immunogens
DE4204650C1 (xx) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5912411A (en) * 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
GB9525639D0 (en) 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US6017758A (en) 1997-02-20 2000-01-25 Vanderbilt University DMNPE caged nucleic acid and vector
EP0991771A2 (en) 1997-03-06 2000-04-12 Klaus Überla Lentivirus based vector and vector system
US6531123B1 (en) * 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
IL132463A0 (en) 1997-05-13 2001-03-19 Univ North Carolina Lentivirus - based gene transfer vectors
US5981830A (en) * 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
EP1717248A1 (en) * 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Tumor targeted vector
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
AU8576298A (en) 1997-07-18 1999-02-10 Chiron Corporation Lentiviral vectors
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
ATE528405T1 (de) 1997-12-22 2011-10-15 Oxford Biomedica Ltd Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
WO1999036511A2 (en) 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
US6084063A (en) 1998-02-06 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitors of allergic reactions
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
WO1999051754A1 (en) * 1998-04-02 1999-10-14 Dana-Farber Cancer Institute, Inc. Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US6555342B1 (en) 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US5989910A (en) * 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
ATE360081T1 (de) * 1998-08-26 2007-05-15 Stuerzl Michael Prof Dr Rer Na Guanylat-bindendes protein (gbp-1) als inhibitor der zellproliferation
AU6139699A (en) 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
ATE424114T1 (de) * 1998-10-01 2009-03-15 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
GB9825524D0 (en) 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
DE19856463B4 (de) 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
EP1165842A4 (en) 1999-03-16 2004-07-07 Dana Farber Cancer Inst Inc LENTIVIRAL VECTOR SYSTEMS FOR SCREENING LARGE QUANTITIES
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AU4559800A (en) * 1999-04-29 2000-11-17 Aarhus Universitet Expression of heterologous genes from an ires translational cassette in retroviral vectors
ES2447115T3 (es) 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
ES2377721T3 (es) 1999-10-12 2012-03-30 Institut Pasteur ADN de triple hélice lentiviral, y vectores y células recombinantes que contienen ADN de triple hélice lentiviral
EP1230394A4 (en) * 1999-11-10 2002-12-18 Uab Research Foundation TRANSDUCTION OF HEMATOPOIETIC STEM CELLS BY LENTIVIRUS VECTOR
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
US6864085B2 (en) * 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
DE60033180T2 (de) 1999-12-14 2007-10-25 Novartis Ag Auf dem rinderimmunschwächevirus (biv) basierte vektoren
AU2001231171B2 (en) * 2000-01-28 2007-01-04 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
IL151781A0 (en) 2000-03-16 2003-04-10 Genetica Inc Methods and compositions for rna interference
WO2001092506A1 (en) 2000-05-30 2001-12-06 University Of Rochester Siv derived lentiviral vector systems
EP1354038A2 (en) * 2000-12-28 2003-10-22 J & J Research Pty Ltd Double-stranded rna-mediated gene suppression
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
JP3765574B2 (ja) 2001-02-22 2006-04-12 三菱化学株式会社 逆向き反復配列を含む組み換え遺伝子及びその利用
US20030039636A1 (en) 2001-05-01 2003-02-27 Genetix Pharmaceuticals, Inc. Novel self-inactivating (SIN) lentiviral vectors
US20030119770A1 (en) * 2001-08-02 2003-06-26 Zhennan Lai Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors
DK1412493T3 (da) * 2001-08-02 2012-01-09 Inst Clayton De La Rech Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer
CA2457282C (en) 2001-09-13 2015-01-13 California Institute Of Technology Method for expression of small antiviral rna molecules within a cell
WO2003072788A1 (en) 2002-02-21 2003-09-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for reversibly controlling expression of target genes in cells

Also Published As

Publication number Publication date
EP1438075A4 (en) 2006-04-19
KR20040054699A (ko) 2004-06-25
US20140335607A1 (en) 2014-11-13
CA2462628C (en) 2019-08-20
CA2462628A1 (en) 2003-04-10
US7198950B2 (en) 2007-04-03
NZ532060A (en) 2005-11-25
RU2305708C2 (ru) 2007-09-10
WO2003029412A3 (en) 2004-02-26
JP2005504539A (ja) 2005-02-17
EP1438075A2 (en) 2004-07-21
WO2003029412A2 (en) 2003-04-10
CN1606456A (zh) 2005-04-13
AU2002343458B2 (en) 2008-03-20
US20170067079A1 (en) 2017-03-09
US9340798B2 (en) 2016-05-17
ZA200402527B (en) 2006-04-26
US20030138954A1 (en) 2003-07-24
CA2915676A1 (en) 2003-04-10
US8748169B2 (en) 2014-06-10
US20070196922A1 (en) 2007-08-23
RU2004113452A (ru) 2005-10-10
CA2915676C (en) 2017-06-06

Similar Documents

Publication Publication Date Title
IL161229A0 (en) Methods and compositions relating to restricted expression lentiviral vectors and their applications.
ZA200103580B (en) Aluminosilicate compositions, preparation and use.
IL195166A0 (en) Interferons, uses and compositions related thereto
TWI317736B (en) Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications
GB0026054D0 (en) Films,compositions and processes
ZA200302929B (en) Compositions comprising cyclohexamantane.
PT1390516E (pt) Novos vectores de expressão e uso dos mesmos
MXPA03007693A (es) Composicion para la piel.
AU2002302570A1 (en) Hair treatment compositions
IL161235A0 (en) Fsh composition, its preparation and use
HUP0401092A3 (en) 5-halogen-6-phenyl-7-fluoralkylamino-triazolopyrimidines as fungicides, preparation and use thereof
MXPA03007314A (es) Composicion para la piel para reducir aceites y grasa de la piel.
AU2002361337A8 (en) Amphoteric polysaccharide, composition and use
EG23378A (en) Composition.
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AP2003002914A0 (en) Novel expression vectors and uses thereof.
EP1390074A4 (en) NEW COMPOSITIONS AND USES THEREOF
GB0125449D0 (en) Cosmetic compositions
AU2002342865A1 (en) Hair treatment compositions
MXPA03008077A (es) Composicion humedecedora para la piel..
GB0129987D0 (en) Skin compositions
MXPA03007549A (es) Composiciones hidrofobicas de reologia modificada, novedosas, agentes de modificacion y metodos de fabricacion.
GB0115344D0 (en) Cosmetic compositions
IL162223A0 (en) 1,3-Diarylprop-2-en-1-ones, compositions containing same and use thereof
ZA200301049B (en) Trichoderma Composition.